<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021982</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-6958-AS-CTIL</org_study_id>
    <nct_id>NCT01021982</nct_id>
  </id_info>
  <brief_title>Evaluation of Objective Perimetry Using Pupillometer</brief_title>
  <official_title>Objective Perimetry in Normal Subjects,Glaucoma Patients and Retinitis Pigmentosa Patients .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel Aviv University, Claire and Amedee Maratier Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective perimetry can better monitor visual field defects in RP and Glaucoma patients than&#xD;
      conventional subjective perimetry.The PLR ( Pupil Light Reflex ) of the short and long wave&#xD;
      ratio should be significantly higher in areas of visual field defects in RP and Glaucoma&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pupil light reflex will be measured by a pupillometer in response to short and long&#xD;
      wavelength light small spot stimulus in different area of the visual field. The PRL will be&#xD;
      measured in four quadrant, central, 10, 20, and 30 degree from the visual axis.&#xD;
&#xD;
      Stimulus duration will be 1000 ms (1 sec), with intervals of 890 ms between stimuli. The&#xD;
      stimuli size V with light intensity of 39.8 cd-s/m2 for both short wavelength stimuli (peak&#xD;
      485 nm) and long wavelength stimuli (peak 620nm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PLR response amplitude and latency</measure>
    <time_frame>Not defined yet</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Glaucoma</condition>
  <condition>Visual Field</condition>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Glaucoma Patients with visual field defects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinitis Pigmentosa</arm_group_label>
    <description>Retinitis Pigmentosa Patients with visual field defects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75&#xD;
&#xD;
          2. Sign on informed consent&#xD;
&#xD;
          3. Papillary response to light.&#xD;
&#xD;
          4. Groups of : Normal , Glaucoma patients with early glaucoma damage on HVF (nasal step&#xD;
             ect. ), Glaucoma patients with advanced glaucoma damage on HVF (arcuate , tubular&#xD;
             vision ) and RP patients (Early VF damage , ring scotoma ) .&#xD;
&#xD;
          5. Refractive correction up to -3.5 D.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cloudy corneas.&#xD;
&#xD;
          2. Surgical intraocular ophthalmic procedure within the past 30 days.&#xD;
&#xD;
          3. Nonreactive pupils.&#xD;
&#xD;
          4. Synechia of the iris to the lens after surgery or inflammation .&#xD;
&#xD;
          5. Neovascularization.&#xD;
&#xD;
          6. Iris coloboma.&#xD;
&#xD;
          7. Sphincter damage due to ischemia or trauma (tears of sphincter or diffuse damage to&#xD;
             muscle).&#xD;
&#xD;
          8. Sphincter damage due to high intraocular pressure .&#xD;
&#xD;
          9. Iris tumor or cyst .&#xD;
&#xD;
         10. Ectropion uvea .&#xD;
&#xD;
         11. Adie's pupil .&#xD;
&#xD;
         12. Optic neuropathy with the potential for producing a positive RAPD (Relative Afferent&#xD;
             Pupillary Defect ).&#xD;
&#xD;
         13. Chronic use of myotics or mydriatics.&#xD;
&#xD;
         14. Systemic Medication which affect on papillary response .&#xD;
&#xD;
         15. Any condition preventing accurate measurement or examination of the pupils.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ygal Rotenstreich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center Tel-Hashomer, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Yoshitomi T, Matsui T, Tanakadate A, Ishikawa S. Comparison of threshold visual perimetry and objective pupil perimetry in clinical patients. J Neuroophthalmol. 1999 Jun;19(2):89-99.</citation>
    <PMID>10380129</PMID>
  </reference>
  <reference>
    <citation>Kalaboukhova L, Fridhammar V, Lindblom B. Relative afferent pupillary defect in glaucoma: a pupillometric study. Acta Ophthalmol Scand. 2007 Aug;85(5):519-25. Epub 2007 Jun 15.</citation>
    <PMID>17573859</PMID>
  </reference>
  <reference>
    <citation>Kardon RH. Pupil perimetry. Curr Opin Ophthalmol. 1992 Oct;3(5):565-70.</citation>
    <PMID>10147922</PMID>
  </reference>
  <reference>
    <citation>Kardon RH, Kirkali PA, Thompson HS. Automated pupil perimetry. Pupil field mapping in patients and normal subjects. Ophthalmology. 1991 Apr;98(4):485-95; discussion 495-6.</citation>
    <PMID>2052302</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 29, 2009</study_first_submitted>
  <study_first_submitted_qc>November 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ygal Rotenstreich</investigator_full_name>
    <investigator_title>Director, Electrophysiology Clinic, Goldschleger Eye Institute</investigator_title>
  </responsible_party>
  <keyword>Pupillometer</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Objective perimetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

